Recent progress has been made in targeting CD47 for cancer immunotherapy [1], and several CD47/SIRPα axis inhibitors have been developed for clinical trials with a favorable antitumor response in solid tumors and hematological malignancies [1, 3, 4]. Here, SIRPA is linked to cancer.